Atley Solutions, Stanford and UC Davis demonstrate proof-of-concept supply chain for astatine-211 in California
Gothenburg, Sweden – 30 May 2026 – Atley Solutions, in collaboration with the Cyclotron & Radiochemistry Facility (CRF) at Stanford University and the Crocker Nuclear Laboratory at UC Davis, today announced the successful demonstration of a proof-of-concept production and logistics workflow for the medical radioisotope astatine-211 (At-211) in California.
The collaboration marks another important step toward scalable and standardized regional access of At-211 for targeted alpha therapies.
The project combines Atley’s proprietary target manufacturing and processing know-how with cyclotron infrastructure at the Crocker Nuclear Laboratory at UC Davis and radiochemistry capabilities at the Cyclotron & Radiochemistry Facility (CRF) at Stanford University. The demonstrated workflow included the manufacture and supply of bismuth targets by Atley, target irradiation at UC Davis Crocker Nuclear Laboratory, transport of the irradiated target to Stanford, and purification of At-211 from the irradiated target via dry distillation on an Atley C100 module installed at Stanford University.
This workflow builds on a standardized approach to the At-211 supply chain already demonstrated in Europe, including the shipment of irradiated bismuth material between production and recipient sites, followed by purification on the Atley C100 module for downstream radiochemistry use.
“We are happy to be re-establishing At-211 production at UC Davis, which was originally developed under a grant from the Department of Energy. Parts of the cyclotron at the Crocker Nuclear Laboratory at UC Davis originate from the Berkeley 60-inch Cyclotron used in the discovery of astatine in 1940, and this project links the isotope’s scientific origins with its modern development for targeted alpha therapy. This relationship with Atley will allow us to focus on beam performance for production while they handle the preparation and recovery.” said Eric Prebys, UC Davis Professor and Director of the Crocker Nuclear Laboratory at UC Davis.
“We are delighted by the successful demonstration of the At-211 workflow in California, which is an important milestone toward expanding our research and clinical development work with At-211,” said Gunilla Jacobson, PhD, Technical & Strategic Director, CRF, Stanford University.
“The whole Atley team is excited to be able to support bringing At-211 back to California,” said Milton Lönnroth, CEO of Atley Solutions. “The successful proof-of-concept shows that our target technology, transport model and Atley C100 purification and synthesis platform can be deployed in a new regional setting. It is a practical step toward building more distributed, reliable and scalable At-211 infrastructure.”
The collaboration demonstrates how standardized production methods, validated logistics workflows and harmonized target technology can support expansion of a distributed At-211 supply network across institutions and geographies. Following further scale-up, the ambition is for the infrastructure and At-211 supply to become available to multiple radiopharmaceutical companies and researchers.
The work was carried out within the framework of a VINNOVA-funded international collaboration between Atley Solutions, Stanford University and Telix Pharmaceuticals under the 2025 “Deepened collaboration with USA, UK and Singapore within Health and Life Science” program. The aim of the collaboration project is to establish the first operational supply chain for At-211 in California.
